The Pebley plaintiff arrives in your office uninsured, gets treated on liens, and runs up six figures of medical bills at rates no carrier would ever pay. Three years later you are at trial, the defense has moved in limine to exclude the billed amounts as unreasonable, and the judge has set a 402 hearing for Friday. What you put in that hearing decides whether the jury hears $185,000 in past medicals or $42,000, and whether your future-care number survives at all.
The post-Pebley admissibility battles have settled into a recognizable pattern. The legal question is no longer whether a lien-treating plaintiff can recover the reasonable value of services; that ground was held in Pebley v. Santa Clara Organics, LLC (2018) 22 Cal.App.5th 1266. The fight now is foundational. Defense counsel concede the doctrine and attack the proof. Recent trial-court rulings, and a small but growing line of appellate guidance after Qaadir v. Figueroa, are reshaping what your treating providers and billing experts need on the stand.
What Pebley actually requires, and what defendants concede
Pebley confirmed that an uninsured plaintiff, or one who chooses to treat outside a carrier network, is not capped at the discounted amounts a hypothetical insurer would have paid under Howell v. Hamilton Meats & Provisions, Inc. (2011) 52 Cal.4th 541. The measure is the reasonable value of services rendered, and the full billed charges are admissible as some evidence of that value. Bermudez v. Ciolek (2015) 237 Cal.App.4th 1311 had already pointed in this direction for genuinely uninsured plaintiffs; Pebley extended the principle to insured plaintiffs who chose to treat on liens.
Defendants have largely stopped trying to relitigate that holding. The current attack runs on two tracks: first, that billed charges are not by themselves evidence of reasonable value without expert foundation; and second, that the lien-purchase market and referral economics so distort the bill that it should be excluded under Evidence Code §352 or sharply limited via §402. Both arguments turn on what you can actually prove about how the bill was generated and what comparable providers charge in the same geographic market.
The 402 hearing as the real gate
Pebley does not exempt billed charges from the usual foundation requirements. Trial courts increasingly treat admissibility as a §402 evidentiary screen on the reasonable-value foundation, separate from the broader §352 prejudice balancing. The plaintiff's billing or treating witness must show that the charges are customary for that provider, that they reflect rates charged to non-litigation patients on liens, and that the rates are not inflated above prevailing market value because litigation is involved.
What gets a witness past that gate is usually a combination of three things: the provider's master charge schedule, evidence that the same code is billed at the same rate regardless of payment source, and outside benchmarks such as FAIR Health regional percentiles, CMS relative value units adjusted by a charge-to-allowed ratio, or comparable surgery-center pricing. A treating surgeon who can only say "this is what I bill" without context is a soft target. A billing administrator with the charge master, the lien agreement, and a defensible market comparison usually clears the threshold.
The corollary point matters: under Corenbaum v. Lampkin (2013) 215 Cal.App.4th 1308, the full billed amount remains inadmissible for plaintiffs who used private health insurance and accepted a negotiated rate. The two paths cannot be mixed in front of the jury, and stipulations on past medicals should track each provider's payment status line by line.
Qaadir and the cross-examination terrain
Qaadir v. Figueroa (2021) 67 Cal.App.5th 790 changed the texture of cross-examination on lien testimony. The court held that evidence of attorney referrals to specific medical providers is generally admissible to show bias, and that evidence of medical-finance companies purchasing the lien at a discount can be relevant, though admissible only with appropriate limiting instructions and not as a damages cap. Qaadir is the case defense counsel cite for nearly every motion to admit referral and lien-sale evidence.
The practical effect is that the plaintiff cannot put the bill in evidence and rest on Pebley. The treating physician will face questions about who referred the patient, what percentage of the practice is attorney-referred, whether the lien has been sold to a third-party funder, and at what discount. Prepare each lien provider for those questions before the deposition. Get the lien-sale documents in your file early so you are not first seeing them at trial. Where the lien has been sold at thirty-five cents on the dollar, that number is likely coming in, but the jury also hears that the provider performed real work at real cost.
Courts after Qaadir have split on the specifics. Some have admitted the lien-purchase price itself; others have admitted only the fact of the sale, treating the discount as collateral-source-adjacent. The defense always asks for the number. Whether you keep it out depends on the §352 record you build, and on whether you can show the sale was a financing transaction rather than an arm's-length valuation of the services.
Documentation that survives the fight
The file that wins the 402 hearing has the following in it well before trial. First, the lien agreement itself, dated and signed at the start of care, with no retroactive language. Second, the provider's full charge master for the relevant CPT codes, plus deposition testimony that those rates apply to all lien patients regardless of who referred them. Third, comparison data: FAIR Health, Medicare allowable multiplied by the regional charge-to-allowed ratio, or affidavits from comparable providers in the same market. Fourth, the treating provider's CV with billing experience disclosed. Fifth, if the lien has been sold, every document related to the sale.
The weakness most often exploited at the 402 stage is a billing rate that exists only on the lien-patient invoice. If the same CPT code shows different prices for cash patients, Medi-Cal patients, and lien patients, and the lien rate is the highest, the court has the §352 hook it needs to limit or exclude. Conversely, where the provider can show the lien rate is the same as the self-pay rate, the foundation usually holds. Our prior coverage of hospital liens under Civil Code §§3045.1–3045.6 walks through how the statutory hospital lien interacts with the Pebley analysis when the same provider holds both a statutory and a contractual lien.
Future medicals: where the doctrine bites hardest
Past charges are easy compared to future-care testimony on liens. The case law on life-care planning requires the future-medical opinion to be tied to the reasonable value of needed care, not the billed value that a future lien provider might charge. A planner who applies the treating surgeon's lien rates to projected procedures is vulnerable to a Sargon motion. The planner needs to anchor each line item in market data, usually FAIR Health 75th or 80th percentile for the relevant geography, with adjustments documented and explained.
Defendants increasingly file Sargon-style challenges to life-care plans built on lien-rate extrapolation. The response is the same as for past medicals: market benchmarks, transparent methodology, and a planner who can explain why a particular percentile reflects what willing buyers actually pay in the relevant region. For verdict-by-verdict patterns on how juries are responding when this foundation is laid, and when it is not, our H1 2026 California verdict survey tracks the spread between cases that survive cross on reasonable value and cases that do not.
Trial mechanics and Medi-Cal interplay
Two procedural points round out the picture. First, the order of proof matters. Many trial courts now require the plaintiff to lay the reasonable-value foundation before the bills reach the jury, rather than admitting the bills conditionally and revisiting at the close of evidence. Plan your case-in-chief so the billing administrator or expert testifies before treating providers reference dollar figures.
Second, the Medi-Cal interplay creates a trap. A plaintiff who treated partly on liens and partly through Medi-Cal cannot recover full billed amounts for the Medi-Cal portion; the Department of Health Care Services has paid an amount, and Howell-Corenbaum caps that line item. The reduction analysis we cover in the Ahlborn process for Medi-Cal lien reduction applies on the recovery side, but the trial admissibility question is separate: keep the Medi-Cal-paid amounts and the lien-billed amounts on separate exhibits, and do not let your billing expert blend them in a single summary chart.
A closing observation
The Pebley fight has become a documentation fight. The doctrine is settled enough that motions in limine rarely turn on the legal question; they turn on whether the plaintiff has built the foundational record. Treat every lien-treated case as if a §402 hearing is coming, because in most California courtrooms one is. The case file that gets prepared in month four, with charge masters, market data, lien agreements, and sale documents, is the one that holds together in month thirty when the defense asks the court to gut the past-medical claim.